| Quality assessment | No of patients | Effect | Quality | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Oxaliplatin | Control | Relative (95% CI) | Absolute | |
| Overall survival | |||||||||||
| 11 | observational studies | none | none | none | serious2 | none | N=20 | - | Median OS=7 months | ⊕○○○ VERY LOW | |
| Progression-free survival | |||||||||||
| 11 | observational studies | none | none | none | serious2 | none | N=20 | - | Median PFS=1.5 months | ⊕○○○ VERY LOW | |
| Overall tumour response (assessed with: WHO criteria) | |||||||||||
| 11 | observational studies | no serious risk of bias | no serious inconsistency | no serious indirectness | serious2 | none | 1/20 (5%) | - | - | - | ⊕○○○ VERY LOW |
| Grade 3-4 Haematological toxicity (assessed with: NCI-CTC) | |||||||||||
| 11 | observational studies | none | none | none | serious2 | none | 0/22 (0%)3 | - | - | - | ⊕○○○ VERY LOW |
| Grade 3 Fatigue (assessed with: NCI-CTC) | |||||||||||
| 11 | observational studies | none | none | none | serious2 | none | 4/20 (20%) | - | - | - | ⊕○○○ VERY LOW |
| Grade 3 Nausea (assessed with: NCI-CTC) | |||||||||||
| 11 | observational studies | none | none | none | serious2 | none | 2/20 (10%) | - | - | - | ⊕○○○ VERY LOW |
| Treatment-related mortality | |||||||||||
| 11 | observational studies | none | none | none | serious2 | none | 1/20 (5%)4 | - | - | - | ⊕○○○ VERY LOW |
| Health-related quality of life | |||||||||||
| 0 | No evidence available | ||||||||||
Small sample size and low number of events limits the precision of this outcome
No haematological toxicity above grade 2 was seen. No symptomatic neutropenia.
One treatment-related death from pulmonary embolism
From: 5, Managing locally advanced or metastatic bladder cancer
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.